**Metastatic**

**HER 2+**
- No Trials Currently Available
- IRB# 18147
  - A Phase 3, Double-blind, Randomized Study of BGB-290 versus Placebo as Maintenance Therapy in Patients with Inoperable Locally Advanced or Metastatic Gastric Cancer that Responded to Platinum-based First-line Chemotherapy

**HER 2-**
- IRB# 18340
  - New study to be available soon

**Localized**
- Localized
  - IRB# 12071
    - New study to be available soon
  - IRB# 16893
    - A Phase I/II Open Label Multi-Center Study of Immune Checkpoint Therapy with Nivolumab for Patients with Locally Advanced Esophageal Squamous Cell Carcinoma

**1st Line**
- IRB# 16058
  - A Randomized, Multicenter, Double Blind, Phase III Study of Adjuvant Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer (CheckMate 577: CHECKpoint pathway and nivolumab clinical Trial Evaluation 577)

**Adjuvant**
- Adjuvant
  - IRB# 12071
    - New study to be available soon

**GI Esophageal / Gastric**

**Key**
- Open for Enrollment
- In Development
- Enrollment on Hold

Source: http://www.ohsu.edu/research/rda/so/knight.php